TerminatedNot Applicable

Longitudinal Evaluation and Real-world Evidence of NT201

Stopped: Corporate Management Decision

United States11 participantsStarted 2023-02-10

Plain-language summary

This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A (BoNT-A) treatment naïve participants.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years of age or older. * Planning treatment with incobotulinumtoxinA. Exclusion Criteria: * Any contraindication to treatment with incobotulinumtoxinA or any other neurotoxins. * Currently pregnant, breastfeeding, or intending to become pregnant during study participation. * Known hypersensitivity to incobotulinumtoxinA or any of its formulation ingredients. * Any infection and/or inflammation at the planned injection points. * Previous treatment with any botulinum toxin products for any aesthetic or therapeutic indications.

What they're measuring

Assessment of FACE-Q Patient-Perceived Age Visual Analogue Scale mean change

Timeframe: Up to 3 years

Trial details

NCT IDNCT05222607

SponsorMerz North America, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-05-18

View on ClinicalTrials.gov More Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face trials